How long does it take to take nintedanib for pulmonary fibrosis

The dosage cycle of Nintedanib (Nintedanib) in the treatment of pulmonary fibrosis is not aimed at "end of treatment", but is based on the concept of long-term maintenance. Pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF) or other progressive interstitial lung diseases, is a chronic, irreversible and progressive disease. Since there is currently no radical cure, the treatment strategy for nintedanib is usually long-term or even lifelong use, provided that the patient tolerates the drug well and the condition does not experience uncontrollable deterioration or severe side effects.

Typically, the recommended dose of nintedanib is 150 mg orally twice daily Taken with meals to reduce gastrointestinal discomfort. Mild side effects may occur at the initial stage of treatment, such as diarrhea, nausea, loss of appetite, etc., but most of these reactions will gradually adapt within 1 to 2 months or be alleviated through dose adjustment. Doctors will closely monitor liver function, weight changes, and gastrointestinal reactions to evaluate whether the patient is suitable for continued long-term use.

In terms of disease course management, nintedanib’s role is to slow down the decline of lung function. According to foreign long-term follow-up studies, such as the INPULSIS study, it has been shown that even if it is used continuously for more than one year, it still has a significant inhibitory effect on the rate of decline in vital capacity. Therefore, most patients with pulmonary fibrosis, provided their condition is stable and there are no serious adverse reactions, will be advised to take the medication continuously for at least 12 months, and whether to continue maintenance treatment will be evaluated based on the pulmonary function test results. Some patients even continue to take it for 3 years or more to minimize the progression of the disease.

In addition, there are individual differences in how quickly patients respond to nintedanib at different stages of disease development. Some patients can feel the maintenance of mobility and relief of cough within a few months of starting treatment; while for other patients, the improvement may be relatively latent, and the effect can only be observed through comparison of pulmonary function tests or imaging data.

Reference materials:https://en.wikipedia.org/wiki/Nintedanib